Theravance Biopharma, Inc. (TBPH)

17.08USD +0.00% (+0.00)

Over 1M: +0.9%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

16.9 16.9 17 17.1
7 Aug 12 Aug 17 Aug 20 Aug 25 Aug 28 Aug 2 Sep

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Operating Income: -6.5M Q3 '25 — Operating Cash Flow: -6.5M Q4 '25 — Operating Income: 20M Q4 '25 — Operating Cash Flow: -6.1M Q1 '26 — Operating Income: -9.5M Q1 '26 — Operating Cash Flow: 73.3M Q2 '26 — Operating Income: -8.3M Q2 '26 — Operating Cash Flow: -7M 0 20M 40M 60M 80M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Gross Profit Operating Income Operating Cash Flow

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

3.5
OE margin 32.7%
Adj. EBITDA margin 16.2%
SBC / sales 18.7%
Oper. margin -4.0%
Accruals 0.014%
Capex / sales 0.04%
FCF margin 51.5%
OCF margin 51.5%
Profit margin 51.6%
ROA 11.5%
ROE 18.6%
ROCE -0.96%
Asset turnover 0.22×
EBITDA margin -2.6%
Gross margin —
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

8.7
EV/OE 14.6×
EV/Sales 4.8×
P/C 2.3×
P/E 16.5×
FCF yield 6.1%
P/B 3.1×
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
PEG —
Shareholder yield —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
Cash-flow margin stability 224.5 pp
Revenue growth in the worst year on record -23.0%
Prepaid revenue growth 0.0%
Gross margin stability across years —
RPO / sales —
RPO growth —
Segment HHI —

2 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.8
Current ratio 13.5×
ND/EBITDA 0.78
Interest cover -1.7×
Debt / Eq 0.0×
Debt payback 0.0 yr
Equity / Assets 61.7%
F-score 7.7 pts
Net debt / Eq 0.0×
Payout 0.0%
Quick ratio 13.5×
Cash / Debt —
Cash runway —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

6.6
Most recent margin move 31.6
Operating margin trend 50.1
Sales/sh Y/Y +28.1%
Sales CAGR 4Y +18.1%
EPS Y/Y +291.6%
Shares change +5.4%
Sales Q/Q -20.9%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS next Y —
Gross profit Y/Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.